Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine hydrochloride oral membrane in moderate-to-severe senile dementia (real-world, multicenter registry)
ChiCTR2300071719Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of memantine in Dementia, Alzheimer's disease (AD), vascular dementia and 1 more, sponsored by Second Hospital of Shandong University. Primary endpoint: mini-mental state examination (MMSE). Planned start May 2023; status: not yet recruiting.
02
Drugs
memantine
03
Conditions
DementiaAlzheimer's disease (AD)vascular dementiafrontotemporal dementia (FTD)
Beyond the preview
Go deeper on ChiCTR2300071719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071719.